Hosted on MSN3d
Boehringer seeks approval of lung disease drug after second Phase III success
Boehringer Ingelheim’s lung disease drug nerandomilast has been successful in a Phase III study paving the way for the ...
Monthly Prescribing Reference21h
Izervay Label Update Removes Limit on Treatment Duration for Geographic Atrophy
The Food and Drug Administration (FDA) has expanded the labeling for Izervay™ (avacincaptad pegol intravitreal solution) to include longer-term ...
The American Journal of Managed Care6d
Phase 3 Data Support Nipocalimab for Myasthenia Gravis
The Vivacity-MG3 study is currently in its open-label extension phase, which is investigating the longer-term safety and ...
U.S. FDA Approves Expanded Label for Astellas' IZERVAY™ (avacincaptad pegol intravitreal solution) for Geographic Atrophy
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced the U.S. Food and Drug Administration (FDA) approved expanded U.S. Prescribing information for IZERVAY™ ...
Convenience Store News17d
FDA Proposes Changes to Food Package Labeling
The proposed nutrition label provides information on saturated ... the FDA's work to develop a "healthy" symbol and the draft Phase II voluntary sodium reduction targets are key aspects of a ...